canceriq and Azra AI Partner to Enhance Lung Cancer Screening with AI

CancerIQ, a developer of cancer risk assessment and treatment management software, is collaborating with azra AI to improve lung cancer screening processes. The partnership integrates canceriq’s risk-based patient identification capabilities with azra AI’s artificial intelligence-powered follow-up tools for low-dose CT (LDCT) scans.

canceriq’s platform assists radiology departments and cancer centers in identifying individuals who could benefit from lung cancer screening. It assesses individual risk factors, provides patient education, and streamlines the scheduling of appropriate LDCT scans. Azra AI offers an enterprise platform that employs AI to track critically important findings, prioritize necessary follow-up actions, and manage patients throughout the screening process.

This collaboration aims to create a more efficient and effective lung cancer screening pathway, potentially leading to earlier detection and improved patient outcomes. By combining risk assessment with AI-driven analysis of scan results, the companies hope to optimize resource allocation and ensure timely intervention for those at higher risk.